HKPD Stock — Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)

Updated October 16, 2026.

HKPD is a Stock. Total return is -96.1% over the past 1.7 years, 127.4 points behind SPY at 31.3%.

Cellyan Biotechnology Co., Ltd is an investment holding company engaged in the over-the-counter pharmaceutical business across Hong Kong and Mainland China, providing cross-border OTC drug procurement and distribution, e-commerce supply chain services, and logistics support including customs clearance, warehousing, and product inspection. The company does not currently have an established distribution schedule. This stock may appeal to investors seeking exposure to the Asia-Pacific pharmaceutical logistics and e-commerce sectors, though investors should note the company was recently incorporated in 2023 and rebranded in December 2025.

HKPD performance versus SPY

Price and return data through 2026-10-16.

Total return is -96.1% over the past 1.7 years, 127.4 points behind SPY at 31.3%. Over the past year its total return — price change plus distributions reinvested — is -90.8%. Its deepest 1-year drawdown was 94.1%.

HKPD key facts

Asset type

Stock

Asset class

Equity

Inception date

01/15/2025

Distribution frequency

None

Last close

$0.11 (as of 2026-10-16)

Market cap

$4,646,854

Average volume

246867.0

Payout ratio

0.0%

EPS

$-0.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HKPD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 94.1%.

Who may consider HKPD — and who may not

It is a weaker fit for investors who need monthly cash flow (HKPD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HKPD

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions